Menu
Carl June, M.D.
Carl June, M.D. is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine. He is also Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. Carl has published more than 500 manuscripts and is the recipient of numerous honors, including election to the National Academy of Medicine, the National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society.
Kole Roybal, Ph.D.
Kole Roybal, Ph.D. is an Associate Professor in the Department of Microbiology and Immunology at the University of California, San Francisco. He is currently a member of the Parker Institute for Cancer Immunotherapy, the Helen Diller Family Comprehensive Cancer Center, and an inaugural Chan Zuckerberg Biohub Investigator. He is also the Deputy Director of the UCSF Center for Synthetic Immunology recently funded by the Cancer Moonshot Initiative. Kole was awarded the Sartorius and Science Magazine Prize for Regenerative Medicine and Cell Therapy and the NIH New Innovator Award in 2018. His body of work was foundational to the next-generation immune cell therapy company, Cell Design Labs, where he was a founding scientist. Cell Design Labs was acquired by Gilead at the end of 2017.
Steven A. Feldman, Ph.D.
Steven Feldman, Ph. D. has more than 20 years of experience as a leader in cell and gene therapy space and is currently the Site Head and Scientific Director for Stanford’s Laboratory of Cell and Gene Medicine, the Stanford GMP Facility where he leads process development and manufacturing efforts to ensure the safe administration of engineered T cell therapy products in support of Stanford Investigator-Initiated and Industry-sponsored clinical trials. Prior to this, Steven was a member of the Surgery Branch, National Cancer Institute (NCI). He established the Surgery Branch Vector Production Facility and manufactured more than 20 clinical-grade viral vector products to support Surgery Branch clinical trials. In addition, he participated in the development and transfer of one of the first commercial CD19-directed CAR-T cell therapies.
Matthew Porteus, M.D., Ph.D.
Matthew Porteus MD, PhD is the Sutardja Chuk Professor of Definitive and Curative Medicine and a Professor in the Department of Pediatrics, Institute of Stem Cell Biology and Regenerative Medicine and Maternal-Child Health Research Institute at Stanford. His primary research focus is on developing genome editing as an approach to cure disease, particularly those of the blood (such as sickle cell disease) but also of other organ systems as well. He received his undergraduate degree at Harvard in History and Science where his honors thesis studied the recombinant DNA controversy of the 1970s. He then completed his MD and PhD training at Stanford, clinical training in Pediatric Hematology/Oncology at Boston Children’s Hospital, and post-doctoral research training with Noble Laureate David Baltimore at CalTech. He works as an attending physician on the Pediatric Hematopoietic Stem Cell Transplant service at Lucile Packard Children’s Hospital where he cares for children under going bone marrow transplantation for both malignant and non-malignant diseases. His goal is to combine his research and clinical interests to develop innovative curative therapies. He served on the 2017 National Academy Study Committee of Human Genome Editing and currently serves on the Scientific Advisory Board for WADA on Cell and Gene Doping and the NIH NexTRAC advisory committee evaluating the emergence of new technologies.